You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Intelligent Agent Toolset for 4D/RCS Architectures

    SBC: 21ST CENTURY SYSTEMS, INC.            Topic: N/A

    There is an increasing demand for systems with more autonomous operations interacting with other autonomous and human-based systems. What is needed is an architecture bundled with developer tools for the creation of intelligent real-time control systems that marry the talents of modern control theory, software technology, sensory processing, and semantic knowledge representations. It would be a st ...

    SBIR Phase I 2006 Department of CommerceNational Institute of Standards and Technology
  2. Antagonists of A2B Adenosine Receptors for Asthma

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): This is a Phase II SBIR proposal to develop a new therapy for the treatment of asthma. The desired outcome will be the identification of a therapeutic candidate to replace theophylline, a non-selective adenosine receptor antagonist that is effective in treating asthma, but limited by side effects, primarily insomnia, mediated by blockade the A1AR in the brain. ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  3. A2A AR Agonists as Adjunct Therapy Against S. aureus Sepsis

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): This is a phase I STTR application to study the efficacy of selective adenosine A2A receptor (A2AR) agonists developed in the laboratories of Adenosine Therapeutics (ATL) in models of Gram-positive bacterial sepsis which will be conducted in the University of Virginia (UVA) laboratories of Dr. Michael Scheld, an expert in the field of infectious disease. Sepsis ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  4. A2a AR Agonists for Rheumatoid Arthritis

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): This is the first revision of a phase I STTR proposal to develop new therapies for the treatment of rheumatoid arthritis (RA). It is collaboration between a biotechnology company, Adenosine Therapeutics, LLC (ATL) based in Charlottesville, VA, and the University of Virginia laboratory of Dr. Donald L. Kimpel, a Rheumatologist experienced in the study of RA. Hum ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  5. Safety of A2A Adenosine Agonist for Treatment of Sepsis

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): ATL146e is a synthetic small molecule developed by Adenosine Therapeutics, LLC (ATL) that acts as a selective agonist of the adenosine A2A receptor. ATL146e, sterile solution for intravenous (i.v.) bolus injection, is currently in Phase III of clinical development for use as a coronary vasodilator in pharmacodynamic stress imaging. ATL146e, when administered pa ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  6. Nanoliter Lab-on-a-chip for Protein Crystallization

    SBC: ADVANCED LIQUID LOGIC            Topic: N/A

    DESCRIPTION (provided by applicant): The human genome contains at least 30,000 unique open reading frames that may yield >100,000 polypeptide products. These products assemble into more than a million biologically relevant structures or proteins of interest per organism. Crystallization and X-ray diffraction of these proteins is routinely performed to determine their 3D structure which needs to be ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  7. Nanoliter Lab-on-a-Chip for Blood Diagnostics

    SBC: ADVANCED LIQUID LOGIC            Topic: N/A

    DESCRIPTION (provided by applicant): Latrogenic blood loss or "bleeding into the laboratory" is an important reason for administration of small volume transfusions in very low birth weight premature 6infants. A direct correlation was found between the volume of blood drawn for diagnostics and subsequent volume transfused. In neonatal infants, there may not be enough collected blood sample to perfo ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  8. Nanoliter Lab-on-a-Chip for Rapid Parallel Immunoassays

    SBC: ADVANCED LIQUID LOGIC            Topic: N/A

    DESCRIPTION (provided by applicant): The development of clinically effective cancer vaccines requires reliable analytical methods to evaluate the immune response to vaccination. Immunoassays are among the most sensitive and specific analytical methods that have been used widely in cancer vaccine research, most commonly to monitor the release of cytokines from T-cells in response to vaccination. A ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  9. Discovery of a Platelet Derived Growth Factor Peptide-based Mimetic

    SBC: AFFINERGY, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Summary/Abstract Diabetic foot ulcers are a significant health problem that imposes high costs on both patients and society (Boulton, Vileikyte et al. 2005). A large proportion of foot ulcers remain unresponsive to available conventional treatment and their associated complications and costs have prompted extensive research that has led to promising breakthroug ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  10. Click Chemistry for Immobilized Bone Morphogenetic Protein

    SBC: AFFINERGY, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): There are over 6.3 million fractures each year in the United States of which approximately 700,000 are difficult to heal. The available treatment options for fractures that do not heal or are slow to heal are limited. Bone morphogenetic proteins are growth factors that stimulate new bone production and have received FDA approval for bone fracture repair and spi ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government